YCH2823 demonstrated potent inhibition of USP7, inhibiting cancer cell growth, promoting G1 phase arrest and apoptosis, increasing p53 and p21 levels, and showing synergistic effects with mTOR inhibitors, making it a promising anticancer agent for both TP53 wild‐type and mutant tumors.432. Here, MTOR is linked to cancer.